MDMA-Assisted Therapy for Treatment-Resistant Posttraumatic Stress Disorder (PTSD) – One step further toward a patient-centered treatment pathway
European Psychiatry June 1, 2022 S. Pratas Penedos, M.j. Freire, I. Fonseca et al.
MDMA-assisted psychotherapy shows promise for treating refractory PTSD. Pre-clinical and imaging studies suggest mechanisms involving memory reconsolidation and fear extinction, driven by increased serotonergic activity and release of oxytocin and brain-derived neurotrophic factor, which reduce amygdala and insula activation while increasing amygdala-hippocampus connectivity. This may create a neuroplastic 'tolerance window' for emotional engagement. A phase 3 randomized, double-blind, placebo-controlled trial reported full remission in 67% of patients at 2 months, with a safety profile comparable to SSRIs and no increase in suicidality, cardiovascular events, or abuse behavior. Emerging models emphasize unmedicated sessions for preparation and integration.